Increased ovarian cancer risk not found in women with breast cancer family historySeptember 21, 2005Women with a strong family history of breast cancer but who don't have breast cancer genetic mutations can now be reassured that they are not at increased risk for ovarian cancer, according to a new study by researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). The work, published in the September 21, 2005, issue of the Journal of the National Cancer Institute, is one of the first prospective studies to allow doctors to tailor ovarian cancer screening recommendations for women with a family history of breast cancer but with no identifiable BRCA mutation. In the ten years since the discovery of BRCA1 and BRCA2 genes, it has been learned that the risk for ovarian cancer in families with mutations in these genes is increased 6- to 61-fold. However, it has also emerged that up to half of families with multiple cases of breast cancer do not have mutations in either BRCA1 or BRCA2. Up until the current study, there has been limited data with which to inform such families as to their risk for ovarian cancer. The MSKCC Clinical Genetics Service studied 199 families with multiple cases of breast cancer but no identified BRCA mutation. During follow-up, 19 new cases of breast cancer were diagnosed - three times more than the six cases that were expected. Only one case of ovarian cancer was diagnosed, which is what researchers would have anticipated in an average risk population. While the authors conclude that women from these families do not have an increased risk of ovarian cancer, they also indicate that the genetic mechanism for up to half of hereditary breast cancer remains unknown. Ongoing research at MSKCC, in collaboration with other scientists in the US, Canada, and Israel, is underway to map undiscovered genes associated with hereditary breast cancer. Memorial Sloan-Kettering Cancer Center |
|||||||||||||||||||||
| Related Ovarian Cancer Current Events and Ovarian Cancer News Articles FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. American Dietetic Association Releases Updated Position Paper Promoting and Supporting Breastfeeding The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible. Metals could forge new cancer drug Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds. Breast cancer patients with high risk gene diagnosed 6 years earlier than generation before Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center. Cancer Predisposition From Gene Variant Shows Strong Gender Bias Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated. Medications Effective in Reducing Risks for Breast Cancer Can Also Cause Serious Side Effects Three drugs that reduce a woman's chance of getting breast cancer also have been shown to cause adverse effects, according to a new report from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health & Human Services. Scientists from University of Hawaii at Manoa find genetic marker A new genetic marker associated with ovarian cancer risk was recently discovered by an international research group, led by scientists from the Cancer Research Genetic Epidemiology Unit in the United Kingdom. New treatment in sight for ovarian cancer In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. Young early stage ovarian cancer patients can preserve fertility A new study finds that young women with early-stage ovarian cancer can preserve future fertility by keeping at least one ovary or the uterus without increasing the risk of dying from the disease. Estrogen-Dependent Switch Tempers Killing Activity of Immune Cells The sex hormone estrogen tempers the killing activity of a specific group of immune cells, the cytotoxic T cells (CTLs), which are known to attack tumor cells and cells infected by viruses. More Ovarian Cancer Current Events and Ovarian Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||